Lower BCL-2 expression level is associated with better outcomes of TNBC patients treated with both adjuvant and neoadjuvant chemotherapy.486 In summary, BCL-2 and BCL-XL are essential biomarkers in tumor prognosis and treatment. The gene discussed is BCL2; the disease is neoplasm.